CrisprBits, a Bengaluru-based biotech startup specialising in CRISPR gene-editing technology, has announced a strategic collaboration with Goa-based Molbio Diagnostics, to revolutionise point of care diagnostics by the introduction of CRISPR in Point-of-Care tests (POCTs).

The strategic partnership between CrisprBits and Molbio Diagnostics represents a significant milestone in the advancement of accessible, cost effective and accurate diagnostic testing in the frontline. The collaboration is set to identify and capitalise on market opportunities, bringing together their respective strengths and expertise.

By harnessing the unprecedented sensitivity and specificity of RNA guide-based target identification of nucleic acid, and the presence of both cis and trans-cleavage property of certain Cas enzymes, CrisprBits has developed a platform to build rapid, precise, and affordable POCTs for a wide range of disease and health conditions.

CrisprBits will spearhead the development of its platform, PathCrisp, for Point-of-Care testing. Simultaneously, Molbio Diagnostics will leverage its large-scale manufacturing capability and well-established sales and marketing network to promote and distribute the developed POCTs worldwide.

The collaboration will focus on building POCTs for swift and accurate detection of various pathogens and genetic markers at the site. The tests will be made available in diverse settings, including clinics, hospitals, and resource-limited areas, where access to reliable diagnostic tools is crucial.